These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15971401)

  • 21. Bioequivalence of rifampicin when administered as a fixed-dose combined formulation of four drugs versus separate formulations.
    Panchagnula R; Kaur KJ; Singh I; Kaul CL
    Methods Find Exp Clin Pharmacol; 2000 Nov; 22(9):689-94. PubMed ID: 11294011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
    Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S322-4; discussion S351-2. PubMed ID: 10593711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioequivalence trials of rifampicin containing formulations: extrinsic and intrinsic factors in the absorption of rifampicin.
    Agrawal S; Singh I; Kaur KJ; Bhade S; Kaul CL; Panchagnula R
    Pharmacol Res; 2004 Sep; 50(3):317-27. PubMed ID: 15225676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S284-5. PubMed ID: 10593705
    [No Abstract]   [Full Text] [Related]  

  • 25. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.
    Milán-Segovia RC; Domínguez-Ramírez AM; Jung-Cook H; Magaña-Aquino M; Romero-Méndez MC; Medellín-Garibay SE; Vigna-Pérez M; Romano-Moreno S
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1454-60. PubMed ID: 20937187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality control of anti-tuberculosis FDC formulations in the global market: part II-accelerated stability studies.
    Ashokraj Y; Kohli G; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Nov; 9(11):1266-72. PubMed ID: 16333936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin.
    Panchagnula R; Agrawal S
    Int J Pharm; 2004 Mar; 271(1-2):1-4. PubMed ID: 15129967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rifampicin serum levels in childhood tuberculosis.
    Thee S; Detjen A; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2009 Sep; 13(9):1106-11. PubMed ID: 19723399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel anti-tuberculosis FDC formulations without reduced bioavailability of rifampicin: from concept to market.
    Singh S; Mariappan TT; Bhutani H
    Int J Tuberc Lung Dis; 2005 Jun; 9(6):701-2. PubMed ID: 15971403
    [No Abstract]   [Full Text] [Related]  

  • 30. Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation.
    Singh C; Bhatt TD; Gill MS; Suresh S
    Int J Pharm; 2014 Jan; 460(1-2):220-7. PubMed ID: 24188983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Herbal modulation of drug bioavailability: enhancement of rifampicin levels in plasma by herbal products and a flavonoid glycoside derived from Cuminum cyminum.
    Sachin BS; Sharma SC; Sethi S; Tasduq SA; Tikoo MK; Tikoo AK; Satti NK; Gupta BD; Suri KA; Johri RK; Qazi GN
    Phytother Res; 2007 Feb; 21(2):157-63. PubMed ID: 17128432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective study.
    Panchagnula R; Kumar Bajpai A; Agrawal S; Ashokraj Y
    Pharmazie; 2006 Oct; 61(10):851-4. PubMed ID: 17069424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of bioavailability of two brands of rifampicin.
    Rewari S; Rath R; Gupta U
    J Assoc Physicians India; 1998 Aug; 46(8):751. PubMed ID: 11229300
    [No Abstract]   [Full Text] [Related]  

  • 34. Bioequivalence study of two pharmaceutical forms of rifampicin capsules in man.
    Chouchane N; Barre J; Toumi A; Tillement JP; Benakis A
    Eur J Drug Metab Pharmacokinet; 1995; 20(4):315-20. PubMed ID: 8983939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited sampling strategies to predict the area under the concentration-time curve for rifampicin.
    Medellín-Garibay SE; Correa-López T; Romero-Méndez C; Milán-Segovia RC; Romano-Moreno S
    Ther Drug Monit; 2014 Dec; 36(6):746-51. PubMed ID: 24784025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosis.
    Nyazema NZ; Rabvukwa P; Gumbo J; Ndudzo P; Chitemerere C
    Cent Afr J Med; 1999 Jun; 45(6):141-4. PubMed ID: 10695183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proposed minimum registration requirements for fixed-dose combination anti-tuberculosis drugs.
    Fourie PB
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S362-7; discussion S381-7. PubMed ID: 10593719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats.
    De Rosa HJ; Baldan HM; Brunetti IL; Ximenes VF; Machado RG
    Biopharm Drug Dispos; 2007 Sep; 28(6):291-6. PubMed ID: 17571294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of bioavailability of two brands of rifampicin.
    Bhatt AD; Revankar SN
    J Assoc Physicians India; 1999 Jul; 47(7):752. PubMed ID: 10778615
    [No Abstract]   [Full Text] [Related]  

  • 40. Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications.
    Court R; Chirehwa MT; Wiesner L; Wright B; Smythe W; Kramer N; McIlleron H
    Int J Tuberc Lung Dis; 2018 May; 22(5):537-543. PubMed ID: 29663959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.